Leading provider of antibody reactome services. Catalog antigen libraries include human proteome, virome & allergome. Custom library creation also possible!
A new Nature Aging study of 5 major cohorts (incl. UK Biobank & ADNI) reveals how APOE2 & APOE4 shape Alzheimer’s risk. Massive, diverse human cohorts are essential for capturing these novel disease mechanisms.
Read more: rdcu.be/fkVs9
Most systems immunology data lacks diversity, relying heavily on European ancestry.
The new HHGP-HK Asian reference cohort (1,025 donors) changes that. Diverse human cohorts are essential to address data gaps, validate biomarkers, & discover novel disease associations globally.
Precision medicine fails as a "one-size-fits-all." By leveraging the UCLA ATLAS Biobank, researchers integrated EHRs with genomic data from 90,000 participants to uncover critical disease-gene links in diverse, underrepresented groups, driving new disease associations.
doi.org/10.1016/j.cell.2026.…#PrecisionMedicine#Genomics#HealthEquity#UCLAATLAS
How do factors like age and genetics shape our immune defense?
New study used antibody reactome profiling to map the human virome at unprecedented resolution. Reactivity data revealed how our "molecular diary" drives vaccine recall and autoimmune risk.
[rdcu.be/ffcYk]
#Immunology#PrecisionMedicine#AntibodyReactomics#NatureImmunology
A new Human Immune Health Atlas published in Nature reveals that immune aging is a non-linear process starting earlier than we thought. By mapping these molecular transitions, we can better tailor vaccines and therapies to biological age, not just the clock.
[rdcu.be/fcrJT]
#ImmuneAgeing#MultiOmics#HumanHealth#Immunology#SystemsBiology#Aging
A new @LifelinesNL study of 700 mother-infant pairs maps dynamics and establishment of the gut virome. Key finding: maternal sharing & early viral diversity are linked to infant immune health and food allergies. Reactomics can now help us unlock how the host response in health and disease.
doi.org/10.64898/2026.03.05.…
Thrilled to welcome Brian McKelligon as the new CEO of Infinity Bio! Brian is an accomplished life sciences leader and we could not be more excited to have him at the helm. His leadership will accelerate the reach of our MIPSA technology and the inSIGHTs it delivers to researchers worldwide.
#InfinityBio#MIPSAbusinesswire.com/news/home/2…
Infinity Bio's Katy Shaw-Saliba & Ben Larman just published a new study screening 85 Ig therapy batches against 283,000 viral peptides, revealing pandemic-driven immune shifts. Discoveries like this begin with decoding the antibody reactome. #AntibodyReactomicsdoi.org/10.1002/eji.70162
Large-scale study in Nature Communications highlights proteomic markers for lymphoid cancer risk up to 10 years pre-diagnosis. Validating findings across multiple large cohorts like UK Biobank provides broad mechanistic insight enabling early detection and targeted prevention.
Read here: rdcu.be/e6GBZ
#Proteomics#PrecisionMedicine#Biomarkers#Lymphoma#EarlyDetection#CancerResearch
Detecting cancer in vague symptoms is tough. A new study applied proteomics to human cohorts (MEDECA/ALLVOS) and found a 29-protein signature that predicts cancer with an AUC of 0.82. This is a great example of biomarker discovery in real-world clinical scenarios.
Read here: rdcu.be/eZ6bE#CancerResearch#Proteomics#EarlyDetection#PrecisionMedicine#Biomarkers